- Home
- GCMGW vs TGTX Comparison
GCMGW vs TGTX Comparison
Compare GCMGW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMGW
- TGTX
- Stock Information
- Founded
- GCMGW 1971
- TGTX 1993
- Country
- GCMGW United States
- TGTX United States
- Employees
- GCMGW 549
- TGTX N/A
- Industry
- GCMGW Finance/Investors Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- GCMGW Finance
- TGTX Health Care
- Exchange
- GCMGW Nasdaq
- TGTX Nasdaq
- Market Cap
- GCMGW N/A
- TGTX 4.2B
- IPO Year
- GCMGW N/A
- TGTX 1995
- Fundamental
- Price
- GCMGW $1.35
- TGTX $32.16
- Analyst Decision
- GCMGW
- TGTX Strong Buy
- Analyst Count
- GCMGW 0
- TGTX 4
- Target Price
- GCMGW N/A
- TGTX $42.50
- AVG Volume (30 Days)
- GCMGW 62.4K
- TGTX 2.1M
- Earning Date
- GCMGW 02-13-2025
- TGTX 11-03-2025
- Dividend Yield
- GCMGW N/A
- TGTX N/A
- EPS Growth
- GCMGW N/A
- TGTX N/A
- EPS
- GCMGW 0.03
- TGTX 0.36
- Revenue
- GCMGW $514,011,999.00
- TGTX $454,069,000.00
- Revenue This Year
- GCMGW N/A
- TGTX $82.58
- Revenue Next Year
- GCMGW N/A
- TGTX $44.99
- P/E Ratio
- GCMGW $33.02
- TGTX $89.15
- Revenue Growth
- GCMGW 15.79
- TGTX 30.96
- 52 Week Low
- GCMGW $2.28
- TGTX $21.16
- 52 Week High
- GCMGW $2.50
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- GCMGW N/A
- TGTX 57.84
- Support Level
- GCMGW N/A
- TGTX $31.34
- Resistance Level
- GCMGW N/A
- TGTX $32.57
- Average True Range (ATR)
- GCMGW 0.00
- TGTX 1.13
- MACD
- GCMGW 0.00
- TGTX 0.54
- Stochastic Oscillator
- GCMGW 0.00
- TGTX 76.20
About GCMGW GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.